Everolimus Related Pneumonitis in MBC

To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Everolimus Infections Lung Diseases Pneumonia Pneumonitis Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with HR+，HER2- metastatic breast cancer
Treated with everolimus for at least one month in metastatic setting
With baseline and at least one follow-up chest CT during everolimus therapy.
Complete medical history

Exclusion criteria

Incomplete medical history
Radiographic imaging unavailable

Treatment and study plan

Primary outcomes

radiographic pattern

Time frame: 2 months

Quantitive measure of lung CT
PFS

Time frame: 2 months

Progression free survival

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Drug-related Pneumonitis During mTOR Inhibitor Therapy in Patients With Metastatic Breast Cancer: A Radiographic Patternbased Approach

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2020
First posted: Nov 5, 2018
Registry last updated: Aug 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed